Idiopathic pulmonary fibrosis and a role for autoimmunity

Gerard F Hoyne, Hannah Elliott, Steven E Mutsaers, Cecilia Prele

    Research output: Contribution to journalArticlepeer-review

    51 Citations (Scopus)


    Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is typically associated with extensive and progressive fibrosis, and is fatal and has limited treatment options. Characteristically IPF patients display large lymphocyte aggregates composed of CD3(+) T cells and CD20(+) B cells within the lung tissue that are located near sites of active fibrosis. In addition, IPF patients can have autoantibodies to a range of host antigens, suggesting a breakdown in immunological tolerance. In this review, we examine the role of T and B cells in IPF pathogenesis and discuss how loss of self-tolerance to lung-specific proteins could exacerbate disease progression in IPF. We discuss what these results mean in terms of future prospects for immunotherapy of IPF.Immunology and Cell Biology advance online publication, 25 April 2017; doi:10.1038/icb.2017.22.

    Original languageEnglish
    Pages (from-to)577–583
    Number of pages7
    JournalImmunology and Cell Biology
    Issue number7
    Early online date25 Apr 2017
    Publication statusPublished - 1 Aug 2017


    Dive into the research topics of 'Idiopathic pulmonary fibrosis and a role for autoimmunity'. Together they form a unique fingerprint.

    Cite this